cfDNA Blood Testing
We focus on analyzing changes in DNA methylation to provide a simple and effective way to detect cancer early. By identifying key signs of cancer in its early stages—often before any symptoms appear—we help patients get professional evaluation and diagnosis sooner.
Catching cancer early means more treatment options and a better chance of recovery. It also helps prevent the disease from getting worse and greatly improves patients' quality of life and chances of survival.
Our Core Technology
DNA methylation testing involves analyzing changes in DNA methylation patterns to gain insights into your health. Research has shown that cancer cells exhibit specific gene methylation changes at early stages, which can serve as significant markers for cancer.
When cancer cells die or undergo necrosis, these unique cancer cell DNA methylation patterns are released into the bloodstream. By simply drawing 8 milliliters of blood and extracting the circulating DNA, methylation analysis can reveal abnormal conditions in certain tissues, providing a fast and precise evaluation of your health status.
The Journey of EG BIOMED
2018-2022
Team Formation, Focused on
Cancer Precision Detection
Technology R&D
2023-2024
Global Positioning and
Technological Innovation
2025-Now
Cancer Detection Technologies
with International Patents
-
Successfully Developed Blood Methylation Detection Technologies for Pancreatic, Lung, Colorectal, and Breast Cancers
-
Core Technologies Patented in the United States, European Union, Singapore, Taiwan, and Multiple Countries
-
Awarded FutureTech Award and National Innovation Award, Gaining International Recognition
-
Breast Cancer Methylation Detection Technology Patented in the United States, Malaysia, China, and Japan
-
Breast Cancer Blood Test Patented in the United States and Singapore
-
Pancreatic Cancer Blood Test Patented in the United States
-
EG BioMed US Inc. Begins Offering Pancreatic Cancer Testing under CLIA Lab
Early Detection
Most cancers are diagnosed at a late stage due to the lack of effective early screening tools. By analyzing DNA methylation changes, we can detect cancer risks earlier, leading to improved treatment outcomes and higher survival rates.
